巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-10-21
2021-08-17
2023-03-31
2021-12-21
2023-02-20
2021-04-14
2022-02-10
2021-11-20
2023-05-15
2021-09-10
2023-03-01
